Abstract: A transparent display apparatus includes a liquid crystal cell and a Sight source opposite to a side surface of the ceil. The cell Includes a first substrate, first electrodes on the first substrate, a second substrate, a second electrode on the first or second substrata, a liquid crystal layer between the two substrates, signal lines on the first substrate, and a light-shielding pattern on the second substrate. The layer is configured to totally reflect or scatter light from the light source incident to a region, opposite to a first electrode, due to action of an electric field provided by the first and second electrodes. At least one signal line has a bottom surface and a light-reflecting side surface facing the light source, and a slope angle therebetween is acute. The pattern is located in a reflection path after a portion of the light irradiates the light-reflecting side surface.

Abstract: A back plate includes a base substrate, gate lines, data lines and power supply lines arranged on the base substrate crossing each other in rows and columns, and pixel structures arranged in an array on the base substrate, each pixel structure includes a driving transistor, a switching transistor connected thereto, and a pixel electrode connected thereto; a gate line and a data line are connected to the switching transistor, and a power supply line is connected to the driving transistor; in a same row or column of pixel structures, a power supply line is arranged between an (2n?1)th pixel structure and an 2n?th pixel structure, and the power supply line is connected to a source electrode of a driving transistor in the (2n?1)th pixel structure and a source electrode of a driving transistor in the 2n?th pixel structure; n is a positive integer greater than or equal to 1.

Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.

Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.